论文部分内容阅读
目的探讨WT1基因、TGF-β1在急性白血病患者中表达及其临床意义。方法入选2008年8月-2010年12月来我院就诊的急性髓系白血病初发(AML组)、经治疗完全缓解的急性髓系白血病患者(AML-CR组)和非恶性血液病组(对照组)各30例,分别采用实时RT-PCR和ELISA检测三组患者骨髓中WT1基因、TGF-β1表达情况,并分析二者之间的相关性。结果分析显示,AML组和AML-CR组WT1 mRNA表达显著高于对照组,差异有统计学意义(P<0.05);AML组WT1 mRNA表达高于AML-CR组,差异有统计学意义(P<0.05);AML组TGF-β1mRNA和TGF-β1蛋白显著低于AML-CR组、对照组,差异有统计学意义(P<0.05);而AML-CR组与对照组之间的差异无统计学意义(P>0.05)。Pearson相关分析显示,对照组和AML-CR组中WT1基因、TGF-β1表达不存在相关性(P>0.05);而在AML组中,WT1基因、TGF-β1存在明显的线性负相关(r=0.724,P<0.05)。结论急性白血病患者存在WT1基因高表达、TGF-β1低表达状态,并且二者存在一定的负相关,同时检测两种指标在白血病患者临床治疗和预后评价上具有一定的临床价值。
Objective To investigate the expression of WT1 gene and TGF-β1 in patients with acute leukemia and its clinical significance. Methods AML patients with acute myeloid leukemia (AML-CR group) and non-hematological malignant disease group (AML group) with acute myeloid leukemia (AML group) were treated in our hospital from August 2008 to December 2010 Control group). The expression of WT1 gene and TGF-β1 in bone marrow of three groups were detected by real-time RT-PCR and ELISA, respectively. The correlation between them was analyzed. The results showed that the expression of WT1 mRNA in AML group and AML-CR group was significantly higher than that in control group (P <0.05), and the expression of WT1 mRNA in AML group was higher than that in AML-CR group (P <0.05) <0.05). The expression of TGF-β1mRNA and TGF-β1 in AML group was significantly lower than that in AML-CR group and control group (P <0.05), but there was no statistical difference between AML-CR group and control group Significance (P> 0.05). Pearson correlation analysis showed that there was no correlation between WT1 gene and TGF-β1 expression in AML-CR group (P> 0.05), but there was a significant linear negative correlation between WT1 gene and TGF-β1 in AML group = 0.724, P <0.05). Conclusion The expression of WT1 gene is high and the expression of TGF-β1 is low in patients with acute leukemia, and there is a certain negative correlation between the two. The detection of both markers has clinical value in the clinical treatment and prognosis evaluation of patients with leukemia.